CRITERIA OF WELL-DIFFERENTIATED THYROID CARCINOMA RESISTANCE TO RADIOIODINE THERAPY

QR Code

CRITERIA OF WELL-DIFFERENTIATED THYROID CARCINOMA RESISTANCE TO RADIOIODINE THERAPY

In patients with well-differentiated thyroid cancer (WDTC) recurrence the metastatic tumor foci in numerous cases are not responded to radioiodine therapy which seriously deteriorate survival prognosis. In this article the contemporary evidential basis is analyzed so as to determine criteria of the...

Full description

Saved in:

Bibliographic Details
Main Authors:	P. O. Rumyantsev, D. K. Fomin, U. V. Rumyantseva
Format:	Article
Language:	Russian
Published:	ABV-press 2015-04-01
Series:	Опухоли головы и шеи
Subjects:	thyroid cancer radioiodine therapy radioiodine-resistant metastases multikinase inhibitors sorafenib
Online Access:	https://ogsh.abvpress.ru/jour/article/view/78
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Brain metastasis from differentiated thyroid carcinoma responding to radioiodine therapy
by: Leo Hashimoto, et al.
Published: (2025-07-01)

Experience in the use of targeted therapy in patients with radio-resistant forms of thyroid cancer in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
by: E. B. Vasil’eva, et al.
Published: (2018-04-01)

Guidelines for radioiodine therapy in differentiated thyroid cancer and post-therapeutic follow-up
by: A. Yu. Shurinov, et al.
Published: (2024-06-01)

Errors in the treatment of highly differentiated thyroid cancer as a multidisciplinary problem
by: N. I. Volkova, et al.
Published: (2021-07-01)

Clinical outcome and influencing factors of differentiated thyroid cancer patients with radioiodine-refractory lung metastasis
by: Congcong Wang, et al.
Published: (2025-08-01)

Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial
by: M. S. Brose, et al.
Published: (2018-07-01)

A practical approach on radioprotection in the treatment of radioiodine for thyroid cancer
by: Janaína Dutra Silvestre Mendes, et al.
Published: (2018-09-01)

Observation and treatment of patients with progressive metastatic differentiated thyroid cancer after establishment of radioiodine refractoriness
by: E. V. Borodavina, et al.
Published: (2024-08-01)

Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice
by: P. O. Rumyantsev, et al.
Published: (2021-11-01)

RADIOIODINE THERAPY OF PAPILLARY THYROID CANCER, COMPLICATED BY A RADIAL MYELITIS. CLINICAL CASE
by: L. M. Farkhutdinova
Published: (2018-06-01)

REFRACTORY OF WELL-DIFFERENTIATED THYROID CANCER TO THE TREATMENT WITH RADIOACTIVE IODINE
by: P. O. Rumyantsev
Published: (2015-04-01)

Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer
by: Jan Taprogge, et al.
Published: (2025-07-01)

Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation
by: E. V. Borodavina, et al.
Published: (2020-04-01)

Neoadjuvant target therapy of differentiated thyroid cancer (clinical observation)
by: P. A. Isaev, et al.
Published: (2017-04-01)

The Impact of Radioiodine (131I) Therapy of Thyroid Disease on Salivary Glands Function and Inflammation: A Comprehensive Review
by: Pietro Bellini, et al.
Published: (2025-06-01)

Selpercatinib in the treatment of medullary and radioiodine-refractory differentiated thyroid cancer with RET mutation (literature review)
by: E. V. Borodavina, et al.
Published: (2025-03-01)

Historical aspects and modern concepts in the treatment of patients with differentiated thyroid cancer, refractory to radioactive iodine therapy
by: E. V. Borodavina, et al.
Published: (2022-02-01)

THE USE OF SORAFENIB (NEXAVAR) IN TREATMENT OF PATIENT WITH DISSEMINATED PARATHYROID CANCER: A CASE REPORT
by: V. A. Gorbunova, et al.
Published: (2017-04-01)

Labeling Peptides with Radioiodine: An Overview of Traditional and Emerging Techniques
by: Vincenzo Patamia, et al.
Published: (2025-07-01)

Lenvatinib in advanced radioiodine-refractory differentiated thyroid cancer: what’s new?
by: E. V. Borodavina, et al.
Published: (2024-12-01)

Side skin reactions of multikinase inhibitors in treatment of thyroid cancer
by: F. S. Sevryukov, et al.
Published: (2021-01-01)

Complete remission of peritoneal strumosis from struma ovarii after radioiodine therapy: a case report
by: Jun Yang, et al.
Published: (2025-06-01)

Thyroid follicular carcinoma complicating with skin metastasis
by: Ali Alkan, et al.
Published: (2016-08-01)

Evaluation of biokinetics and dosimetry in [131I]-NaI therapies: whole-body images quantification versus lower limb region
by: Bianca Lemos Lima, et al.
Published: (2020-06-01)

Survival analysis of patients with advanced metastatic differentiated thyroid cancer
by: E. V. Borodavina, et al.
Published: (2022-08-01)

Prolonged duration of response in lenvatinib responders with thyroid cancer (Russian translation)
by: A. G. Gianoukakis, et al.
Published: (2018-11-01)

TSHR in thyroid cancer: bridging biological insights to targeted strategies
by: Shaojie Xu, et al.
Published: (2025-07-01)

Algorithm of stepwise medical rehabilitation of patients with differentiated thyroid cancer
by: T. I. Grushina, et al.
Published: (2021-04-01)

Incidence of Adverse Events Related to Therapies with sodium iodine (131I): Contribution to the Pharmacovigilance in Brazil
by: Jaqueline Cardena Fernandes, et al.
Published: (2024-09-01)

Advanced metastatic radioiodine refractory differentiated thyroid cancer: current treatment and dynamic surveillance issues
by: E. V. Borodavina, et al.
Published: (2025-03-01)

Tall-cell variant of papillary thyroid carcinoma: literature review and case reports
by: E. V. Borodavina, et al.
Published: (2020-11-01)

Value of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in staging of patients with differentiated thyroid cancer after thyroidectomy during the first course of radioiodine therapy
by: T. M. Geliashvili, et al.
Published: (2021-01-01)

Exophytic pancreatic lymphoepithelial cyst incidentally detected in a differentiated thyroid cancer patient on whole-body I-131 scan: a case report
by: Takahiro Murokawa, et al.
Published: (2022-02-01)

The utility of quantitative 18F-FDG PET/CT-derived parameters as prognostic factors for predicting overall survival in radioiodine-refractory differentiated thyroid cancer
by: Mai Son, et al.
Published: (2025-07-01)

New-generation mutitargeted tyrosine kinase inhibitors in the treatment of radioactive iodine-refractory differentiated thyroid cancer
by: A. M. Mudunov
Published: (2015-06-01)

CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I
by: P. A. Isaev, et al.
Published: (2015-04-01)

<sup>18</sup>F-fluorodeoxyglucose positron emission tomography combined with computed tomography for the prediction of radioiodine therapy response in patients with metastatic differentiated thyroid cancer
by: T. M. Geliashvili, et al.
Published: (2020-02-01)

The use of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in patients with differentiated thyroid cancer after initial treatment
by: T. M. Geliashvili, et al.
Published: (2017-04-01)

Specificity of hand-foot skin reaction induced by multikinase inhibitors: clinical, histological and ultrasound characteristics
by: E. A. Shatokhina, et al.
Published: (2020-07-01)

Treatment Outcomes of Systemic Therapies for Infiltrative Hepatocellular Carcinoma
by: Chen PY, et al.
Published: (2025-06-01)